The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss—up to 24% with ...

The quest for weight loss has taken a dramatic turn. A wave of new-age solutions, from once-weekly injectables like Wegovy ...

Novo Nordisk has submitted a new, higher dose of its obesity treatment, Wegovy, for approval to the European Medicines Agency ...

Wegovy® is indicated for chronic weight management in adults and adolescents (12+) with obesity or overweight and at least ...

Eli Lilly and Novo Nordisk dominate the weight-loss drug market. But pharma companies like Amgen, Viking, Zealand, Structure, ...

We have witnessed weight loss of 13–15% with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and up to 18–23% with the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) ...

Weight-loss drugs are this decade’s blockbuster medicines. Drugs like Ozempic, Wegovy, and Mounjaro help people with diabetes ...